CCL2 and Patent ductus arteriosus: Remarkably, both CAF phenotypes showed significantly higher expression of CCL2 compared with primary or metastatic carcinoma cells, which is consistent with scRNA-Seq data and moderate correlations between iCAF or myCAF transcript markers and CCL2 in human PDA (Figure 3I).